Advertisement

Topics

Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

23:03 EDT 12 Mar 2018 | Drugs.com

AUSTIN, TX -- (Marketwired) -- 03/13/18 -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today the initiation of a Phase 2a clinical study, OPTIMA, evaluating its lead product candidate Molgradex, an inhaled formulation of...

Original Article: Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

NEXT ARTICLE

More From BioPortfolio on "Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...